Search for author "Vojtech Melenovsky"
155 Results
- You have accessRestricted accessEvidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection FractionClinical PerspectiveMasaru Obokata, Yogesh N.V. Reddy, Sorin V. Pislaru, Vojtech Melenovsky and Barry A. BorlaugCirculation. 2017;136:6-19, originally published April 5, 2017https://doi.org/10.1161/CIRCULATIONAHA.116.026807
- Table 1.You have accessEvidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection FractionClinical PerspectiveMasaru Obokata, Yogesh N.V. Reddy, Sorin V. Pislaru, Vojtech Melenovsky, Barry A. BorlaugCirculation July 2017, 136 (1) 6-19; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.026807By Masaru Obokata, Yogesh N.V. Reddy, Sorin V. Pislaru, Vojtech Melenovsky and Barry A. Borlaug
- Table 2.You have accessEvidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection FractionClinical PerspectiveMasaru Obokata, Yogesh N.V. Reddy, Sorin V. Pislaru, Vojtech Melenovsky, Barry A. BorlaugCirculation July 2017, 136 (1) 6-19; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.026807By Masaru Obokata, Yogesh N.V. Reddy, Sorin V. Pislaru, Vojtech Melenovsky and Barry A. Borlaug
- Figure 1.You have accessEvidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection FractionClinical PerspectiveMasaru Obokata, Yogesh N.V. Reddy, Sorin V. Pislaru, Vojtech Melenovsky, Barry A. BorlaugCirculation July 2017, 136 (1) 6-19; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.026807By Masaru Obokata, Yogesh N.V. Reddy, Sorin V. Pislaru, Vojtech Melenovsky and Barry A. BorlaugBody mass, cardiac remodeling, and relationships between N-terminal pro-B-type natriuretic peptide (...Show MoreBody mass, cardiac remodeling, and relationships between N-terminal pro-B-type natriuretic peptide (NT-proBNP) and left ventricular (LV) filling pressures. A and B, Increased body mass was associated with larger right ventricular (RV) size and total heart volume. C, Pulmonary capillary wedge pressure (PCWP) was directly correlated with NT-proBNP in all patients with heart failure with preserved ejection fraction (HFpEF), but the relationship was shifted upward in obese HFpEF, indicating a higher PCWP for any value of NT-proBNP compared with nonobese HFpEF. (D) In contrast, the correlations between LV transmural pressure (LVTMP) and NT-proBNP did not differ in obese and nonobese HFpEF.Show Less
- Table 3.You have accessEvidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection FractionClinical PerspectiveMasaru Obokata, Yogesh N.V. Reddy, Sorin V. Pislaru, Vojtech Melenovsky, Barry A. BorlaugCirculation July 2017, 136 (1) 6-19; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.026807By Masaru Obokata, Yogesh N.V. Reddy, Sorin V. Pislaru, Vojtech Melenovsky and Barry A. Borlaug
- Figure 2.You have accessEvidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection FractionClinical PerspectiveMasaru Obokata, Yogesh N.V. Reddy, Sorin V. Pislaru, Vojtech Melenovsky, Barry A. BorlaugCirculation July 2017, 136 (1) 6-19; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.026807By Masaru Obokata, Yogesh N.V. Reddy, Sorin V. Pislaru, Vojtech Melenovsky and Barry A. BorlaugCorrelations between left ventricular filling pressures, adiposity, and plasma volume. Elev...Show MoreCorrelations between left ventricular filling pressures, adiposity, and plasma volume. Elevations in left heart filling pressures were related to greater body mass (A) and plasma volume (B) in obese heart failure with preserved ejection fraction (HFpEF) but not in nonobese HFpEF. PCWP indicates pulmonary capillary wedge pressure.Show Less
- Figure 3.You have accessEvidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection FractionClinical PerspectiveMasaru Obokata, Yogesh N.V. Reddy, Sorin V. Pislaru, Vojtech Melenovsky, Barry A. BorlaugCirculation July 2017, 136 (1) 6-19; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.026807By Masaru Obokata, Yogesh N.V. Reddy, Sorin V. Pislaru, Vojtech Melenovsky and Barry A. BorlaugExercise capacity and hemodynamic reserve is reduced in obese heart failure with preserved ejection...Show MoreExercise capacity and hemodynamic reserve is reduced in obese heart failure with preserved ejection fraction (HFpEF). A, Compared with control subjects, the increase in cardiac index was lower in both nonobese and obese HFpEF but similar between the groups. B, The efficiency of translating metabolic work (Vo2) to external ergometric work (cycling Watts) was lower in subjects with obese HFpEF compared with nonobese HFpEF and control subjects. C, Peak Vo2 was inversely correlated with body mass. D, Peak exercise pulmonary artery mean pressure (mPAP) was higher in subjects with obese than in both subjects with nonobese HFpEF and control subjects. This was explained by impaired pulmonary vasodilation with exercise in subjects with obese HFpEF compared with both subjects with nonobese HFpEF and control subjects, evidenced by greater decreases in pulmonary artery compliance index (PACI) and less reduction in pulmonary vascular resistance index (PVRI; E and F). Error bars indicate SEM. *P<0.05 vs control subjects. †P<0.05 vs nonobese HFpEF.Show Less
- Figure 4.You have accessEvidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection FractionClinical PerspectiveMasaru Obokata, Yogesh N.V. Reddy, Sorin V. Pislaru, Vojtech Melenovsky, Barry A. BorlaugCirculation July 2017, 136 (1) 6-19; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.026807By Masaru Obokata, Yogesh N.V. Reddy, Sorin V. Pislaru, Vojtech Melenovsky and Barry A. BorlaugPericardial restraint and ventricular interdependence are enhanced in obese heart failure with prese...Show MorePericardial restraint and ventricular interdependence are enhanced in obese heart failure with preserved ejection fraction (HFpEF). A, Compared with patients with nonobese HFpEF and control subjects, patients with obese HFpEF displayed greater total epicardial heart volume. B, Representative short-axis echocardiographic images of the mitral valve and midcavity levels at end diastole in obese HFpEF. The septum becomes flattened and less convex to the right ventricle (RV) at end diastole, indicative of enhanced ventricular interaction. C and D, This was further supported by higher left ventricular (LV) eccentricity index and right atrial pressure (RAP)/PCWP ratio in subjects with obese HFpEF compared with nonobese HFpEF and control subjects. *P<0.05 vs control subjects. †P<0.05 vs nonobese HFpEF.Show Less
- Figure 5.You have accessEvidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection FractionClinical PerspectiveMasaru Obokata, Yogesh N.V. Reddy, Sorin V. Pislaru, Vojtech Melenovsky, Barry A. BorlaugCirculation July 2017, 136 (1) 6-19; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.026807By Masaru Obokata, Yogesh N.V. Reddy, Sorin V. Pislaru, Vojtech Melenovsky and Barry A. BorlaugInteractions between pericardial restraint, pulmonary artery pressures, and filling pressures in sub...Show MoreInteractions between pericardial restraint, pulmonary artery pressures, and filling pressures in subjects with heart failure with preserved ejection fraction (HFpEF). A and B, Compared with nonobese HFpEF, left ventricular (LV) eccentricity index was greater in obese HFpEF for any given value of pulmonary artery (PA) systolic pressure both at end diastole and end systole, suggesting that septal distortion in obese HFpEF was not simply related to more right ventricular (RV) afterload mismatch. C, The increase in right atrial pressure (RAP; which approximates pericardial pressure) relative to oxygen consumption (Vo2) was greater in subjects with obese HFpEF than in both subjects with nonobese HFpEF and control subjects with exercise. D, The pulmonary capillary wedge pressure (PCWP) required to achieve any given distending LV pressure (transmural pressure [LVTMP]) was shifted upward in obese HFpEF. See text for details. *P<0.05 vs control subjects. †P<0.05 vs nonobese HFpEF.Show Less
- You have accessRestricted accessPercutaneous Pericardial ResectionCLINICAL PERSPECTIVEA Novel Potential Treatment for Heart Failure With Preserved Ejection FractionBarry A. Borlaug, Rickey E. Carter, Vojtech Melenovsky, Christopher V. DeSimone, Prakriti Gaba, Ammar Killu, Niyada Naksuk, Lilach Lerman and Samuel J. AsirvathamCirculation: Heart Failure. 2017;10:e003612, originally published April 10, 2017https://doi.org/10.1161/CIRCHEARTFAILURE.116.003612
Pages
Journal
Article Type
Article Type
- ACE/Angiotension receptors 3
- Arrhythmia/Electrophysiology 1
- Basic Science 1
- Brief Reviews 6
- Cardiac Failure and Remodeling IV 1
- Cell biology/structural biology 3
- Cell signalling/signal transduction 3
- Chronic ischemic heart disease 3
- Clinical Science 3
- Clinical Studies 3
- Clinical Track 7
- Clinical Trialists 1
- Clinical genetics 3
- Congestive 36
- Contractile function 11
- Core 5. Myocardium: Function and Failure 8
- Core 5: Myocardium: Development, Function, and Failure 3
- Correspondence 2
- Echocardiography 10
- Echocardiography: Novel Approaches for Assessment of LV Function I 2
- Endothelium/vascular type/nitric oxide 3
- Exercise testing 9
- Exercise/exercise testing/rehabilitation 3
- Function/Metabolism 1
- Functional genomics 3
- Gene expression 3
- Gene regulation 3
- Genetics of cardiovascular disease 3
- Glucose intolerance 3
- Growth factors/cytokines 3
- Heart Failure 13
- Heart Failure and Cardiomyopathies 2
- Heart Failure: Pharmacologic Therapy 1
- Hypertension - basic studies 3
- Images in Cardiovascular Medicine 1
- Imaging 1
- Lipids 3
- Mechanism of atherosclerosis/growth factors 3
- Novel Approaches to Pharmacologic Intervention in Heart Failure 1
- Original Article 51
- Original Articles 35
- Original Articles Original Article Original Articles 35
- Original Research 10
- Original Research Article 19
- Other Treatment 3
- Other Vascular biology 3
- Other arteriosclerosis 3
- Other diabetes 3
- Other diagnostic testing 9
- Other etiology 3
- Other heart failure 10
- Other hypertension 3
- Oxidant stress 3
- Pathophysiology 3
- Physiological and pathological control of gene expression 3
- Poster Abstract Presentations 2
- Poster Abstract Presentations Poster Session 2 1
- Poster Session 2 2
- Pulmonary Hypertension: Novel Therapies and Imaging Methods 1
- Pulmonary circulation and disease 10
- Receptor pharmacology 3
- Remodeling 11
- Risk Factors 3
- Session Title: Clinical and Hospital-Based Observational Studies II 1
- Session Title: Heart Failure: Cardiac Mechanics and Hemodynamic Changes 1
- Session Title: Heart Failure: Heart Failure with Preserved Ejection Fraction 1
- Session Title: Heart Failure: Molecular Cardiology/Pathophysiology 1
- Session Title: Heart Failure: Pathophysiology and Biomarkers 1
- Session Title: Heart Failure: Pathophysiology and Diagnosis 1
- Session Title: Heart Failure: Pathophysiology and Diagnosis I 1
- Session Title: Magnetic Resonance Imaging (MRI): Heart / T1 Mapping / Spectroscopy 1
- Session Title: Metabolic Remodeling in Heart Failure: Discoveries for Translation 1
- Session Title: Molecular Markers of Heart Failure 1
- Session Title: Predicting Mortality in Heart Failure 1
- Session Title: Ventricular Function/Hemodynamics and Biomarkers 1
- Smooth muscle proliferation and differentiation 3
- Structure 8
- Type 2 diabetes 3
- Ventricular Function: Basic Mechanisms I 1
- Volume 113, Issue 4 Supplement; August 2, 2013 / Abstracts From the American Heart Association’s Basic Cardiovascular Sciences 2013 Scientific Sessions 2
- Volume 128, Issue 22 Supplement; November 26, 2013 / Abstracts From the American Heart Association 2013 Scientific Sessions and Resuscitation Science Symposium 4
Subject
Subject
- ACE/Angiotension receptors 6
- Arrhythmias, clinical electrophysiology, drugs 1
- CPR and emergency cardiac care 1
- CV surgery: valvular disease 1
- Cardiovascular Pharmacology 1
- Cell biology/structural biology 6
- Cell signalling/signal transduction 6
- Chronic ischemic heart disease 6
- Clinical Studies 6
- Clinical genetics 6
- Congestive 84
- Contractile function 23
- Echocardiography 17
- Electrophysiology 1
- Endothelium/vascular type/nitric oxide 6
- Exercise 19
- Exercise testing 28
- Exercise/exercise testing/rehabilitation 7
- Functional genomics 6
- Gene expression 6
- Gene regulation 6
- Genetics of cardiovascular disease 6
- Glucose intolerance 6
- Growth factors/cytokines 6
- Heart Failure 42
- Hemodynamics 14
- Hypertension 9
- Hypertension - basic studies 6
- Hypertrophy 1
- Lipids 6
- Mechanism of atherosclerosis/growth factors 6
- Myocardial cardiomyopathy disease 10
- Obesity 10
- Other Treatment 6
- Other Vascular biology 6
- Other arteriosclerosis 6
- Other diabetes 6
- Other diagnostic testing 18
- Other etiology 6
- Other heart failure 20
- Other hypertension 6
- Oxidant stress 6
- Pacemaker 1
- Pathophysiology 20
- Pericardial Disease 9
- Physiological and pathological control of gene expression 6
- Pulmonary circulation and disease 20
- Receptor pharmacology 6
- Remodeling 22
- Risk Factors 6
- Smooth muscle proliferation and differentiation 6
- Structure 16
- Type 2 diabetes 6
- Valvular heart disease 1
- Volume 113, Issue 4 Supplement; August 2, 2013 / Abstracts From the American Heart Association’s Basic Cardiovascular Sciences 2013 Scientific Sessions 2
- Volume 128, Issue 22 Supplement; November 26, 2013 / Abstracts From the American Heart Association 2013 Scientific Sessions and Resuscitation Science Symposium 4
Content Type
Resource Type
- Articles 42
- Tables & Figures 107
- HWTABLE 6




